Access to Medicine

Bora follows the Access to Medicine Index guidelines to build the group policy and implementation strategies commits to do our best to keep products available at affordable prices and ensure patients receive medicines they need.

• Promise of Support™ Program

Our subsidiary, Upsher-Smith, launches the Promise of Support™ Program for our rare disease portfolio. The rare disease prescription drug brands under this program will offer services and support that meet the Promise of Support™ standard.

A rare disease often creates significant financial, emotional, physical and psychological challenges for patients and families. Gaining access to critical prescription drugs to support rare disease patients can be an added burden to an already difficult situation. For the branded prescription drugs we provide for rare disease, Upsher-Smith is committed to continuously learning about the unique challenges for each disease state and each therapy. We will do our best to provide value-added services and support that reduce friction in the drug therapy journey.

Currently there are 3 products covered by this program, including Vigadrone® and TORPENZ™.

• Drug Research, Development and Registration

Bora established our strong footprint of developing hard-to-formulate and controlled release generic pharmaceutical products for US market through the past decade, providing affordable and accessible high quality essential medicine to the patients.

To further address the unmet medical needs, we have shifted our focus of research and development from generic products to innovative medicines. We are actively working to expand our product portfolio and enhance our approach to R&D so we can deliver more medicines to more patients faster. Our focused therapeutic area is central nervous system diseases (CNS), with further concentrating on epilepsy/seizure, ADHD, and depression, especially for pediatric patients.